Category : Science and TechPublished on: June 11 2024
Share on facebook
The Institute of Advanced Virology (IAV) in Kerala has developed non-infectious Nipah virus-like particles (VLPs), a significant advancement for India's vaccine production and monoclonal antibody (MAB) development against the Nipah virus.
These VLPs, created using three structural proteins of the Nipah virus, can be used for laboratory diagnostics, vaccine production, and testing the prevention of Nipah virus entry into target cells, inducing immunity without being infectious.
This breakthrough reduces India's dependence on imported antibodies and aligns with efforts, like those by the Indian Council of Medical Research (ICMR) and Serum Institute of India (SII), to locally manufacture MABs for compassionate use in treating Nipah virus infections.
